trial
as of 2026-07-01Lurasidone Pediatric Pharmacokinetics Study
NCTId NCT01620060
at a glance
Phase 1 · Completed
Enrollment 105 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2013-05
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
105 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2012-06
Primary completion
2013-05
Eligibility
ALL · 6 Years · 17 Years
Interventions & indications
Drugs
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Lurasidone Medical Director, MDStudy Director
Sites
10 total
Little Rock, United StatesSpringdale, United StatesMurrieta, United StatesFort Lauderdale, United StatesSouth Miami, United StatesAtlanta, United StatesCincinnati, United StatesCleveland, United StatesPhiladelphia, United StatesOrem, United States
Facts & assertions
4 sourced
Enrollment
105
Phase
PHASE1
Primary Completion Date
2013-05
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator